BioMarin Pharmaceutical (BMRN) Stock Forecast, Price Target & Predictions
BMRN Stock Forecast
BioMarin Pharmaceutical stock forecast is as follows: an average price target of $101.70 (represents a 60.36% upside from BMRN’s last price of $63.42) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
BMRN Price Target
The average price target for BioMarin Pharmaceutical (BMRN) is $101.70 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $65.00. This represents a potential 60.36% upside from BMRN's last price of $63.42.
BMRN Analyst Ratings
According to 17 Wall Street analysts, BioMarin Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for BMRN stock is 0 'Strong Buy' (0.00%), 11 'Buy' (64.71%), 6 'Hold' (35.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioMarin Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Olivia Brayer | Cantor Fitzgerald | $90.00 | $67.00 | 34.33% | 41.91% |
| Oct 30, 2024 | Jack Allen | Robert W. Baird | $65.00 | $69.91 | -7.02% | 2.49% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $81.00 | $69.91 | 15.86% | 27.72% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $79.00 | $69.59 | 13.51% | 24.57% |
| Oct 04, 2024 | Gena Wang | Barclays | $86.00 | $69.51 | 23.72% | 35.60% |
| Sep 18, 2024 | David Lebowitz | Citigroup | $93.00 | $71.14 | 30.73% | 46.64% |
| Sep 17, 2024 | George Farmer | Scotiabank | $78.00 | $71.21 | 9.54% | 22.99% |
| Sep 17, 2024 | Joon Lee | Truist Financial | $90.00 | $71.20 | 26.40% | 41.91% |
| Sep 17, 2024 | William Pickering | Bernstein | $90.00 | $69.86 | 28.83% | 41.91% |
| Sep 17, 2024 | Kostas Biliouris | BMO Capital | $115.00 | $71.13 | 61.68% | 81.33% |
The latest BioMarin Pharmaceutical stock forecast, released on Oct 30, 2024 by Olivia Brayer from Cantor Fitzgerald, set a price target of $90.00, which represents a 34.33% increase from the stock price at the time of the forecast ($67.00), and a 41.91% increase from BMRN last price ($63.42).
BioMarin Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 16 | 25 |
| Avg Price Target | $78.67 | $95.38 | $97.64 |
| Last Closing Price | $63.42 | $63.42 | $63.42 |
| Upside/Downside | 24.05% | 50.39% | 53.96% |
In the current month, the average price target of BioMarin Pharmaceutical stock is $78.67, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 24.05% increase as opposed to BioMarin Pharmaceutical's last price of $63.42. This month's average price target is down -17.52% compared to last quarter, and down -19.43% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Wedbush | Neutral | Outperform | Upgrade |
| Oct 30, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Oct 30, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Oct 30, 2024 | William Blair | Sector Perform | Sector Perform | Hold |
| Oct 30, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Oct 30, 2024 | Citigroup | Neutral | Neutral | Hold |
| Oct 30, 2024 | William Blair | Sector Perform | Market Perform | Downgrade |
| Oct 04, 2024 | William Blair | Sector Perform | Sector Perform | Hold |
| Oct 04, 2024 | Wells Fargo | Underperform | Underperform | Hold |
| Sep 18, 2024 | Citigroup | Neutral | Neutral | Hold |
BioMarin Pharmaceutical's last stock rating was published by Wedbush on Nov 04, 2024. The company Upgrade its BMRN rating from "Neutral" to "Outperform".
BioMarin Pharmaceutical Financial Forecast
BioMarin Pharmaceutical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $646.21B | $581.33B | $595.27M | $596.41M | $537.54M | $505.34M | $533.80M | $519.36M | $449.81M | $408.74M | $501.69M | $486.07M | $452.12M | $476.78M | $429.49M | $502.07M | $454.44M | $461.10M |
| Avg Forecast | $846.96M | $863.59M | $840.29M | $832.33M | $790.44M | $774.03M | $755.36M | $726.94M | $713.49M | $703.43M | $663.98M | $651.83M | $638.82M | $603.84M | $595.23M | $570.35M | $537.62M | $518.45M | $520.20M | $510.95M | $442.38M | $435.30M | $448.31M | $446.35M | $439.33M | $457.38M | $418.62M | $468.58M | $457.91M | $455.76M |
| High Forecast | $884.13M | $901.48M | $877.17M | $868.86M | $825.13M | $808.00M | $788.51M | $767.56M | $728.74M | $703.94M | $665.25M | $652.09M | $663.25M | $660.00M | $621.35M | $595.38M | $561.21M | $518.45M | $520.20M | $510.95M | $442.38M | $435.30M | $448.31M | $446.35M | $439.33M | $457.38M | $418.62M | $468.58M | $457.91M | $455.76M |
| Low Forecast | $791.65M | $807.19M | $785.41M | $777.98M | $738.82M | $723.48M | $706.03M | $669.37M | $685.08M | $702.92M | $662.71M | $651.56M | $625.52M | $573.53M | $556.36M | $533.11M | $502.51M | $518.45M | $520.20M | $510.95M | $442.38M | $435.30M | $448.31M | $446.35M | $439.33M | $457.38M | $418.62M | $468.58M | $457.91M | $455.76M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 19 | 9 | 6 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1011.57% | 962.72% | 1.00% | 1.05% | 1.00% | 0.97% | 1.03% | 1.02% | 1.02% | 0.94% | 1.12% | 1.09% | 1.03% | 1.04% | 1.03% | 1.07% | 0.99% | 1.01% |
BioMarin Pharmaceutical's average Quarter revenue forecast for Mar 24 based on 6 analysts is $651.83M, with a low forecast of $651.56M, and a high forecast of $652.09M. BMRN's average Quarter revenue forecast represents a -99.90% decrease compared to the company's last Quarter revenue of $646.21B (Dec 23).
BioMarin Pharmaceutical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 19 | 9 | 6 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $14.22B | $25.66B | $99.98M | $86.88M | $10.62M | $27.58M | $63.98M | $57.34M | $-37.34M | $-15.45M | $45.06M | $55.02M | $-8.08M | $-24.98M | $-9.53M | $134.23M | $22.43M | $42.99M |
| Avg Forecast | $50.59M | $51.59M | $50.20M | $49.72M | $47.22M | $46.24M | $45.12M | $43.42M | $42.62M | $42.02M | $39.66M | $261.07M | $38.16M | $36.07M | $35.56M | $237.34M | $-41.07M | $20.14M | $20.21M | $253.84M | $17.18M | $16.91M | $17.41M | $162.69M | $17.06M | $17.77M | $16.26M | $18.20M | $17.79M | $17.70M |
| High Forecast | $52.81M | $53.85M | $52.40M | $51.90M | $49.29M | $48.27M | $47.10M | $45.85M | $43.53M | $42.05M | $39.74M | $313.29M | $39.62M | $39.43M | $37.12M | $284.81M | $-32.85M | $20.14M | $20.21M | $304.61M | $17.18M | $16.91M | $17.41M | $195.22M | $17.06M | $17.77M | $16.26M | $18.20M | $17.79M | $17.70M |
| Low Forecast | $47.29M | $48.22M | $46.92M | $46.47M | $44.13M | $43.22M | $42.18M | $39.99M | $40.92M | $41.99M | $39.59M | $208.86M | $37.37M | $34.26M | $33.23M | $189.87M | $-49.28M | $20.14M | $20.21M | $203.07M | $17.18M | $16.91M | $17.41M | $130.15M | $17.06M | $17.77M | $16.26M | $18.20M | $17.79M | $17.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 372.61% | 711.41% | 2.81% | 0.37% | -0.26% | 1.37% | 3.17% | 0.23% | -2.17% | -0.91% | 2.59% | 0.34% | -0.47% | -1.41% | -0.59% | 7.38% | 1.26% | 2.43% |
6 analysts predict BMRN's average Quarter EBITDA for Mar 24 to be $261.07M, with a high of $313.29M and a low of $208.86M. This is -98.16% lower than BioMarin Pharmaceutical's previous annual EBITDA (Dec 23) of $14.22B.
BioMarin Pharmaceutical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 19 | 9 | 6 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $20.38B | $40.38B | $56.04M | $50.85M | $-249.00K | $-6.65M | $27.66M | $120.80M | $-57.90M | $-36.49M | $12.94M | $17.37M | $22.10M | $784.80M | $-29.18M | $81.38M | $15.02M | $55.04M |
| Avg Forecast | $46.59M | $52.62M | $56.29M | $62.16M | $151.14M | $153.82M | $142.54M | $126.13M | $108.53M | $104.68M | $70.54M | $190.75M | $38.87M | $43.28M | $41.67M | $173.41M | $-63.69M | $-2.41M | $6.60M | $185.46M | $-72.68M | $-50.14M | $-21.89M | $51.37M | $-33.71M | $50.13M | $-22.58M | $498.05M | $-7.32M | $11.82M |
| High Forecast | $49.24M | $55.62M | $59.50M | $65.71M | $159.77M | $162.59M | $150.67M | $153.82M | $117.45M | $105.56M | $70.56M | $228.90M | $51.24M | $72.79M | $44.05M | $208.09M | $-50.95M | $-2.41M | $6.60M | $222.55M | $-72.68M | $-50.14M | $-21.89M | $61.64M | $-33.71M | $50.13M | $-22.58M | $597.66M | $-7.32M | $11.82M |
| Low Forecast | $42.63M | $48.15M | $51.51M | $56.88M | $138.31M | $140.76M | $130.44M | $95.37M | $93.66M | $103.79M | $70.53M | $152.60M | $34.45M | $23.61M | $38.13M | $138.72M | $-76.43M | $-2.41M | $6.60M | $148.37M | $-72.68M | $-50.14M | $-21.89M | $41.09M | $-33.71M | $50.13M | $-22.58M | $398.44M | $-7.32M | $11.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 524.19% | 932.91% | 1.34% | 0.29% | 0.00% | 2.76% | 4.19% | 0.65% | 0.80% | 0.73% | -0.59% | 0.34% | -0.66% | 15.66% | 1.29% | 0.16% | -2.05% | 4.66% |
BioMarin Pharmaceutical's average Quarter net income forecast for Mar 24 is $190.75M, with a range of $152.60M to $228.90M. BMRN's average Quarter net income forecast represents a -99.06% decrease compared to the company's last Quarter net income of $20.38B (Dec 23).
BioMarin Pharmaceutical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 19 | 9 | 6 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $275.02B | $223.93B | $215.34M | $223.00M | $245.74M | $216.82M | $196.84M | $194.62M | $217.60M | $183.30M | $184.20M | $174.30M | $195.54M | $179.45M | $175.40M | $202.97M | $204.89M | $187.18M |
| Avg Forecast | $339.17M | $345.83M | $336.50M | $333.31M | $316.54M | $309.96M | $302.49M | $291.11M | $285.72M | $281.69M | $265.89M | $307.31M | $255.82M | $241.81M | $238.36M | $279.38M | $239.36M | $207.64M | $208.34M | $298.80M | $177.17M | $174.34M | $179.55M | $178.76M | $175.95M | $183.18M | $167.65M | $187.66M | $183.39M | $182.53M |
| High Forecast | $354.05M | $361.00M | $351.26M | $347.94M | $330.43M | $323.57M | $315.76M | $307.37M | $291.83M | $281.90M | $266.40M | $368.78M | $265.60M | $264.30M | $248.82M | $335.25M | $287.23M | $207.64M | $208.34M | $358.56M | $177.17M | $174.34M | $179.55M | $178.76M | $175.95M | $183.18M | $167.65M | $187.66M | $183.39M | $182.53M |
| Low Forecast | $317.02M | $323.24M | $314.52M | $311.54M | $295.86M | $289.72M | $282.73M | $268.05M | $274.34M | $281.49M | $265.38M | $245.85M | $250.49M | $229.67M | $222.80M | $223.50M | $191.49M | $207.64M | $208.34M | $239.04M | $177.17M | $174.34M | $179.55M | $178.76M | $175.95M | $183.18M | $167.65M | $187.66M | $183.39M | $182.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1075.08% | 926.05% | 0.90% | 0.80% | 1.03% | 1.04% | 0.94% | 0.65% | 1.23% | 1.05% | 1.03% | 0.98% | 1.11% | 0.98% | 1.05% | 1.08% | 1.12% | 1.03% |
BioMarin Pharmaceutical's average Quarter SG&A projection for Mar 24 is $307.31M, based on 6 Wall Street analysts, with a range of $245.85M to $368.78M. The forecast indicates a -99.89% fall compared to BMRN last annual SG&A of $275.02B (Dec 23).
BioMarin Pharmaceutical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 19 | 9 | 6 | 6 | 12 | 19 | 18 | 9 | 8 | 8 | 11 | 15 | 17 | 9 | 9 | 10 | 11 | 7 | 7 | 9 | 8 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.11 | $214.53 | $0.30 | $0.27 | $-0.00 | $-0.04 | $0.15 | $0.66 | $-0.32 | $-0.20 | $0.07 | $0.10 | $0.12 | $4.33 | $-0.16 | $0.45 | $0.08 | $0.31 |
| Avg Forecast | $0.24 | $0.27 | $0.29 | $0.32 | $0.77 | $0.78 | $0.72 | $0.64 | $0.55 | $0.53 | $0.36 | $0.31 | $0.20 | $0.22 | $0.21 | $0.16 | $-0.06 | $-0.01 | $0.03 | $0.21 | $-0.36 | $-0.25 | $-0.11 | $-0.09 | $-0.17 | $0.25 | $-0.11 | $0.03 | $-0.04 | $0.06 |
| High Forecast | $0.25 | $0.28 | $0.30 | $0.33 | $0.81 | $0.82 | $0.76 | $0.78 | $0.60 | $0.54 | $0.36 | $0.32 | $0.26 | $0.37 | $0.22 | $0.16 | $-0.05 | $-0.01 | $0.03 | $0.21 | $-0.36 | $-0.25 | $-0.11 | $-0.09 | $-0.17 | $0.25 | $-0.11 | $0.03 | $-0.04 | $0.06 |
| Low Forecast | $0.22 | $0.24 | $0.26 | $0.29 | $0.70 | $0.71 | $0.66 | $0.48 | $0.48 | $0.53 | $0.36 | $0.31 | $0.17 | $0.12 | $0.19 | $0.14 | $-0.06 | $-0.01 | $0.03 | $0.21 | $-0.36 | $-0.25 | $-0.11 | $-0.09 | $-0.17 | $0.25 | $-0.11 | $0.03 | $-0.04 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.56% | 977.18% | 1.42% | 1.74% | 0.02% | 2.98% | 4.56% | 3.11% | 0.88% | 0.80% | -0.64% | -1.12% | -0.71% | 17.32% | 1.42% | 14.49% | -2.19% | 5.26% |
According to 6 Wall Street analysts, BioMarin Pharmaceutical's projected average Quarter EPS for Mar 24 is $0.31, with a low estimate of $0.31 and a high estimate of $0.32. This represents a 183.48% increase compared to BMRN previous annual EPS of $0.11 (Dec 23).
BioMarin Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.57 | $45.38 | 144.37% | Buy |
| LEGN | Legend Biotech | $38.19 | $82.69 | 116.52% | Buy |
| MREO | Mereo BioPharma Group | $3.53 | $6.75 | 91.22% | Buy |
| LQDA | Liquidia | $9.84 | $17.17 | 74.49% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| IONS | Ionis Pharmaceuticals | $34.34 | $51.68 | 50.50% | Buy |
| PCVX | Vaxcyte | $86.83 | $124.00 | 42.81% | Buy |
| TECH | Bio-Techne | $67.57 | $91.69 | 35.70% | Buy |
| HALO | Halozyme Therapeutics | $45.65 | $57.00 | 24.86% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| INCY | Incyte | $75.87 | $84.56 | 11.45% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| AGIO | Agios Pharmaceuticals | $53.78 | $48.00 | -10.75% | Buy |
| EXEL | Exelixis | $34.45 | $30.50 | -11.47% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |